Related Experiment Video
Updated: Jul 6, 2026
06:55
Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Randomized controlled trials in health technology assessment: overkill or overdue?
1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA. bentzen@humonc.wise.edu
Summary
Randomized controlled trials are crucial for radiation oncology advancements. However, process measures are more sensitive than clinical outcomes for evaluating new health technologies like intensity modulated photon vs. proton radiotherapy.
Area of Science:
- Radiation Oncology
- Evidence-Based Medicine
- Health Technology Assessment
Background:
- Evidence-based medicine (EBM) is integral to radiation oncology.
- Randomized controlled trials (RCTs) are the gold standard for comparing therapies.
- Assessing health technologies requires robust methodologies.
Purpose of the Study:
- To evaluate the role of process measures versus clinical outcomes in assessing health technologies.
- To illustrate concepts using the intensity modulated photon vs. proton radiotherapy debate.
- To discuss equipoise and health economics in technology assessment.
Main Methods:
- Critically assessed the utility of clinical outcome measures in detecting quality improvements.
- Examined process measures and operational characteristics for health technology evaluation.
- Utilized the intensity modulated photon vs. proton radiotherapy comparison as a case study.
Main Results:
- Clinical outcome measures have low sensitivity and specificity for detecting quality improvements in health technologies.
- Process measures and operational characteristics are more effective for evaluating treatment quality.
- RCTs, while valuable, may need complementary methods for technology assessment.
Conclusions:
- Radiation oncology needs enhanced methodologies beyond traditional RCTs for health technology assessment.
- Process measures are vital for evaluating quality improvements in radiotherapy.
- Further development in critical assessment methodology is essential for radiation oncology researchers.
Related Concept Videos
01:13Randomized Experiments
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...